Overview

Duloxetine Versus Placebo in the Treatment of FMS

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Boehringer Ingelheim

Treatments:

Duloxetine Hydrochloride